Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the ... a weight loss pill in the U.S. before its key rival does so. The company markets the popular weight-loss drug, Wegovy.

To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now looking at the next generation of weight loss drugs ... who are unsure as to why the remaining patients reduced ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported ... be able to introduce a weight loss pill in the U.S. before its key rival does so. The company markets the ...

It said not doing so would be more expensive in the long term. Vials of Wegovy at a Novo Nordisk production line in Hillerod, Denmark. The company argues government subsidies for its weight-loss ...

Novo also said only 57.3% of patients reached the highest dose of the medicine, but didn't explain why ... Novo Nordisk and its race to increase production of its new weight-loss drug helped ...